Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.
about
Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Increase in antibody-dependent ...... on under lenalidomide therapy.
@en
Increase in antibody-dependent cellular cytotoxicity
@nl
type
label
Increase in antibody-dependent ...... on under lenalidomide therapy.
@en
Increase in antibody-dependent cellular cytotoxicity
@nl
prefLabel
Increase in antibody-dependent ...... on under lenalidomide therapy.
@en
Increase in antibody-dependent cellular cytotoxicity
@nl
P2093
P2860
P356
P1476
Increase in antibody-dependent ...... ion under lenalidomide therapy
@en
P2093
Arno Amann
Brigitte Kircher
Daniel Putzer
Gabriele Gamerith
Heinz Zwierzina
Judith Loeffler-Ragg
Thomas Auer
Wolfgang Hilbe
P2860
P304
P356
10.4161/CBT.27327
P577
2013-12-18T00:00:00Z